On July 15 & 16, 2019 at Harvard Business School, join us in exploring how advances in cell and gene therapy, drug development, and bioengineering in regenerative medicine are moving from the lab to the patient – and what it will take to identify real, lasting value for business and society.

Breakthrough technologies are thrilling in their novelty and can be transformative in their application, but regenerative medicine technologies defy the normal paradigms of both business model development and market-potential assessment. How does one ‘define value’ when considering such a new technology? How does one ‘create value’ when building a company on a novel platform? In today’s market, how does one price such an innovation in different healthcare systems?

At the 12th annual Business of Regenerative Medicine: *Defining and Creating Value*, you will engage with CEO’s, venture capitalists, experts in biomedical research, and patient advocates to make sense of this complex and shifting landscape. In two days of panel discussions, presentations, and networking, our distinguished speakers will provide insights – as well as guardrails – for navigating the emerging industry of regenerative medicine.

Agenda

**Arrival | July 14**  
**WELCOME RECEPTION**  
Guest speaker: **George Q. Daley, MD, PhD**, Dean of the Faculty of Medicine, Harvard Medical School  
Location: TBD | Late afternoon

**Day 1 | July 15**  
**DEFINING VALUE**

**Aldrich Hall 112**

**BREAKFAST**  
8:00-9:00

Opening address:  
9:00-9:30  
**OPENING KEYNOTE | A SHARED MISSION: DISCOVERY, DEVELOPMENT, REPEATABILITY, AND COMMERCIALIZATION IN ACADEMIA AND BUSINESS**  
Mark Fishman, MD*, Harvard (formerly NIBR, MGH)  
A shared mission: discovery, development, repeatability, and commercialization in academia and business

**REGISTER NOW AT:**  
https://brm2019.hscl.harvard.edu
BUILDING A RESILIENT COMPANY
9:30-10:15  Sarah Larson*, Third Rock Ventures

BREAK
10:15-10:30

TURNING EARLY SCIENTIFIC VALUE INTO COMMERCIAL VALUE
10:30-11:30  Moderator – (Charles River Labs?)
State Government – Amritha Jaishanker, PhD*, MD Stem Cell Research Fund
Academic funds – Curtis Keith, PhD*, Blavatnik Accelerator
Hospital venture – Roger Kitterman*, Partners Innovation Fund
Govt entity – Keith Thompson*-UK Cell and Gene Catapult

HOW IS VALUE DEFINED BY DIFFERENT TYPES OF INVESTORS?
11:30-12:30  Moderator – (Charles River Labs?)
Life Sciences VC – Amir Nashat, ScD*, Polaris Ventures
Corporate VC - Jason Hafler, PhD*, Sanofi Ventures
Foundation – Chris Colecchi, MPH*, Broadview Ventures
Incubator- Ann Dewitt, PhD, MBA*, The Engine, MIT

LUNCH
12:30-1:30

INTRODUCTION OF ARM AND ECONOMIC IMPACT STUDY
1:30-1:35  David Smith*, Of Counsel, Pepper Hamilton LLP

INDUSTRY OVERVIEW
1:35-1:45  Janet Lambert*, CEO, Alliance of Regenerative Medicine

GENERATING VALUE: WHAT DIFFERENT INVESTORS EXPECT
1:45-2:30  Moderator: Janet Lambert*
Financial markets: Reni Benjamin, PhD*, Raymond James Co.
Big pharma: Co with RM unit – Stefan Wildt, PhD*, Takeda

CAPTURING VALUE – PRICING A CURE FOR THE GOOD OF SOCIETY
2:30-3:30  Moderator: Morrie Ruffin*, Alliance for Regenerative Medicine
Harvard Business School: Amitabh Chandra, PhD*, HBS
IQVIA - Adrian McKemey, PhD or John Doyle, Dr.PH, MPH*
Harvard Pilgrim Healthcare – Michael Sherman, MD*
Evidera - Eric Faulkner, MPH*

BREAK
3:30-3:40

LEADERSHIP IN HIGH-RISK ENVIRONMENTS
3:50-4:30  Nancy Koehn, PhD*, HBS
Move to HBS Spangler Center | Williams Room

RECEPTION
5:00-6:00

DINNER
6:00-8:00

   PERSPECTIVES ON A DISEASE | RESEARCHER AND PATIENT ADVOCATE
   Jayaraj Rajagopal, MD*, (MGH, CF researcher)
   and Joan Finnegan Brooks* (CF patient advocate)

Day 2 | July 16

Aldrich Hall 112

BREAKFAST
8:00-9:00

Opening Address
9:00-9:30

   CREATING VALUE THROUGH CONVERGENCE OF DISCIPLINES
   Sangeeta Bhatia, PhD*, MIT/BWH

Talk
9:30-10:00

   SUITING TECHNOLOGY TO BUSINESS MODEL AND FINANCING
   Luk Vandenberghe, PhD*, MEEI – Akouos, GenSight, Odylia

Talk
10:00-10:30

   THE STEPS FROM ACADEMIC STUDIES TO SRA TO VENTURE INCUBATION TO PUBLIC COMPANY
   Jason Gardner, PhD*, CEO, President and Co-Founder, Magenta Therapeutics

BREAK
10:30-10:45

Talk
10:45-11:15

   WHY REPLACE CELLS WHEN YOU CAN TURN THEM ON OR OFF?
   Albert Edge, PhD*, MEEI – Decibel Therapeutics

Talk
11:15 – 11:45

   WHY USE CELLS WHEN YOU CAN USE THEIR OUTPUT?
   Steven Stice, PhD* – ArunA Biomedical

Panel
11:45-12:30

   VALUE OF IN VITRO MODELS
   Vik Khurana, PhD*, BWH – Yumanity (cells in a dish)
   Geraldine Hamilton, PhD*, – Emulate (organ on a chip)
   Kimberly Homan, PhD*, Lewis Lab, Harvard – bioprinting and organoids (vascularizing 3D models)
LUNCH
12:30 – 1:30

Discussion
12:45 – 1:15
THE PROSPECTS FOR iPS-BASED THERAPIES-THE VIEW FROM THE US AND JAPAN
Marcie Glicksman, PhD*, Orig3n
TBA, FujiFilm

Panel
1:30 – 2:45
HOW DO BIOMATERIALS WORK WITH CELLS AND GENES TO PROVIDE BETTER SOLUTIONS?
Dan Anderson, PhD*, MIT – Microencapsulation for Immune Protection
Jennifer Elisseeff, PhD*, Johns Hopkins – Tissue regeneration
Paula Hammond, PhD*, MIT

Talk
2:45 – 3:15
THE CEO’S PERSPECTIVE
Geoff MacKay*  Lessons learned from running a cell therapy company (Organogenesis), and launching a gene therapy company (AvroBio)

Closing Address
3:15 – 4:00
THE FUTURE OF REGENERATIVE MEDICINE – THE INTERSECTION OF GENETIC ENGINEERING AND CELL THERAPY
George Church, PhD*, Harvard Medical School

* = confirmed participation